Alamar Biosciences | 8-K: FY2026 Q2 Revenue: USD 29.43 M

Revenue: As of FY2026 Q2, the actual value is USD 29.43 M.

EPS: As of FY2026 Q2, the actual value is USD -0.22.

EBIT: As of FY2026 Q2, the actual value is USD -13.33 M.

Second Quarter 2026 Financial Highlights (Three Months Ended June 30)

Revenue

Alamar Biosciences, Inc. generated total revenue of $29.4 million for the second quarter of 2026, an 82% increase compared to $16.2 million in the corresponding prior-year period. Instrument revenue grew 35% to $7.8 million, up from $5.8 million in the prior-year period. Consumable revenue increased 147% to $15.5 million, from $6.3 million in the prior-year period. Services and other revenue rose 49% to $6.2 million, compared to $4.1 million in the prior-year period.

Gross Profit and Margin

Gross profit for the second quarter of 2026 was $17.7 million, compared to $8.6 million in the prior-year period. The gross margin was 60% for the second quarter of 2026, an increase from 53% in the corresponding prior-year period.

Operating Expenses

Total operating expenses were $31.3 million for the second quarter of 2026, an 89% increase from $16.5 million in the prior-year period. Research and development expenses were $13.8 million, up from $8.9 million in the prior-year period. Selling, general and administrative expenses were $17.4 million, compared to $7.6 million in the prior-year period.

Operating Loss

Alamar Biosciences, Inc. reported an operating loss of - $13.5 million for the second quarter of 2026, compared to an operating loss of - $7.9 million in the corresponding prior-year period.

Net Loss

Net loss for the second quarter of 2026 was - $13.2 million, higher than the - $7.0 million net loss recorded in the prior-year period.

Other Income and Expenses

• Interest income, net, was $1.9 million for the second quarter of 2026, up from $0.6 million in the prior-year period.
• Interest expense was - $0.2 million, compared to - $0.05 million in the prior-year period.
• Loss on remeasurement of convertible notes was - $1.4 million in the second quarter of 2026, with no comparable loss in the prior-year period.
• Other (expense) income, net, was - $0.03 million, compared to $0.3 million in the prior-year period.
• Provision for income taxes was - $0.09 million in the second quarter of 2026.

Stock-Based Compensation

Total stock-based compensation expense for the second quarter of 2026 was $3.3 million, compared to $0.7 million in the prior-year period.

Six Months Ended June 30, 2026 Financial Highlights

Revenue

Total revenue for the six months ended June 30, 2026, was $55.5 million, compared to $29.3 million for the corresponding period in 2025. Product revenue was $44.6 million, up from $21.2 million in the prior-year period. Service and other revenue was $10.9 million, compared to $8.0 million in the prior-year period.

Gross Profit

Gross profit for the six months ended June 30, 2026, was $32.2 million, compared to $15.0 million in the prior-year period.

Operating Expenses

Total operating expenses for the six months ended June 30, 2026, were $58.1 million, compared to $31.4 million in the prior-year period. Research and development expenses were $26.8 million, up from $17.2 million in the prior-year period. Selling, general and administrative expenses were $31.2 million, compared to $14.2 million in the prior-year period.

Operating Loss

Loss from operations for the six months ended June 30, 2026, was - $25.9 million, compared to - $16.5 million in the prior-year period.

Net Loss

Net loss for the six months ended June 30, 2026, was - $34.5 million, compared to - $14.7 million in the prior-year period.

Cash and Investments

As of June 30, 2026, Alamar Biosciences, Inc. had $256.3 million in cash, cash equivalents, short-term investments, and restricted cash.

Operational Metrics

Alamar Biosciences, Inc. launched the first commercial multiplexed blood-based immunoassay for eMTBR-tau and expanded its strategic partnership with the Alzheimer’s Disease Data Initiative and Gates Ventures. The company also launched the NULISAseq™ Immune 340 Panel, its broadest multiplexed immune profiling solution.

Outlook / Guidance

Alamar Biosciences, Inc. projects full-year 2026 revenue to be between $116 million and $120 million, representing an expected growth of 59% at the midpoint compared to full-year 2025. The company believes it is well-positioned to sustain momentum into the coming quarters due to recent product launches.